Medical Xpress September 3, 2024
Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, who are at greatest risk of developing severe COVID-19, according to researchers in the Center for Translational Antiviral Research at Georgia State University’s Institute for Biomedical Sciences.
While it’s best to begin treatment earlier, in immunocompromised hosts, drugs like paxlovid and molnupiravir appear to inhibit replication of the virus even if they are initiated up to 14 days after infection.
The study, published in the Journal of Virology, offers new information about late-onset treatment introduced 14 days after infection with SARS-CoV-2, the virus that causes COVID-19. The findings demonstrate that antiviral therapeutics could have valuable clinical use in...
Today's Sponsors
Today's Sponsor